Franklin Biotechnology Discovery Fund A(acc)USD
Franklin Templeton Investment Funds (SICAV domiciled in Luxembourg)
Key Information
Legal Documents
Performance
Analysis

Fund Profile

Category: SICAV

Franklin Biotechnology Discovery Fund (the “Fund”) aims to increase the value of its investments over the medium to long term. The Fund invests mainly in: · equity securities issued by biotechnology companies of any size located in the U.S. and other countries The Fund can invest to a lesser extent in: · higher-quality debt securities issued by corporate issuers A biotechnology company is one that earns at least 50% of its profits from, or is devoted to, activities such as research, development, manufacture, and distribution of various biotechnological or biomedical products, services and processes. The Fund will usually invest more in the U.S. than in any other country. You may request the sale of your shares on any Luxembourg business day. The income received from the Fund's investments is accumulated with the result of increasing the value of the shares. For further information on the Objectives and Investment Policy of the Fund, please refer to the section “Fund Information, Objectives and Investment Policies” of the current prospectus of Franklin Templeton Investment Funds. The benchmark of the Fund is the NASDAQ Biotechnology Index. The benchmark is indicated for information purposes only, and the Fund manager does not intend to track it. The Fund can deviate from this benchmark. Terms to Understand Debt securities: Securities representing the issuer’s obligation to repay a loan at a specified date and to pay interest. Equity securities: Securities that represent an ownership stake in a company.

Morningstar Rating
More information about the calculation of the Morningstar Ratings
Neutral
Neutral
Risk and reward profile
7
Lower Risk
Possible Lower
Returns
Higher Risk
Possible Higher
Returns
Key Information
Closing Price 01/12/202043.72
Morningstar categorySector Equity Biotechnology
CurrencyUSD
Distribution statusAccumulating
ISINLU0109394709
Inception Date03/04/2000
Minimum initial amount100.00 USD
Fees And Charges
Entry feeNone
Custody feeNone
Exit feeNone
Ongoing charge1.82% of which 0.75% is paid to MeDirect
Fund management company
AddressFranklin Templeton International Services S.à r.l. 8A, rue Albert Borschette Luxembourg L-1246 Luxembourg
Manager NameEvan S. McCulloch
Manager Start Date01/11/2000
Websitewww.franklintempleton.lu
Total Net Assets (mil)1,897.69 USD (31/10/2020)
UCITSYes
AdministratorFranklin Templeton International Services S.à r.l.

Documents

Prospectus
en 01/09/2020
Annual Report
en 30/06/2020
Semi Annual Report
en 31/12/2019
Morningstar Report
02/12/2020

Performance

Historical returns are no guarantee for future performances. Investing in Financial markets and securities involves risk. Past performance is not a guarantee of future results. Investment losses may occur and investors could lose some or all of their investment in the Fund.
Entry fees, purchase charges, custody fees, exit fees, sale charges and taxes are not included in the calculation of past performance. Ongoing charges (including management fees, administrative fees and other costs) have been taken in to account, as they are already included in the price/NAV of the fund.
The performance in euro can be lower or higher than the performance in the currency of denomination of the fund due to fluctuations in exchange rates.
Annualised performance in USD
PeriodAnnualised returnDate
1 year27.84%01/12/2020
3 years12.70%01/12/2020
5 years5.65%01/12/2020
10 years16.25%01/12/2020
Since launch7.40%01/12/2020
Cumulative performance in USD
Performance
YTD 01/01/202023.64
1 month11.93
3 months11.87
6 months13.62
Quarterly Returns
Q 1Q 2Q 3Q 4
2020-13.09%28.70%3.21%-
201918.88%3.56%-14.51%26.87%
2018-0.19%2.98%4.61%-22.16%
201712.20%1.81%8.67%-5.81%
2016-24.31%1.56%14.09%-6.37%
Dividend

Asset Allocation
% Long% Short% Net Assets
Stock94.38%0.00%94.38%
Bond0.00%0.00%0.00%
Cash4.63%0.00%4.63%
Other0.99%0.00%0.99%
Return/Risk Analysis
Risk Measurement1 Year3 Years5 Years
Standard Deviation
23.6324.2024.95
Sharpe Ratio
---
Sortino Ratio
---
Positive Months9.0021.0034.00
Negative Months3.0015.0026.00
Worst Month-9.32-14.76-22.73
World Regions
Region%
United States84.22
United Kingdom3.11
Asia - Emerging2.60
Canada2.31
Europe - ex Euro1.08
Eurozone1.05
Stock Sector Weighting
Sector% of Equity
Healthcare93.29
Financial Services1.09
Top 10 Holdings
HoldingSectorCountry% of Assets
Gilead Sciences Inc HealthcareUnited States6.53
Regeneron Pharmaceuticals Inc HealthcareUnited States6.26
Vertex Pharmaceuticals Inc HealthcareUnited States5.30
Amgen Inc HealthcareUnited States5.14
Iovance Biotherapeutics Inc HealthcareUnited States4.02
Illumina Inc HealthcareUnited States3.59
Horizon Therapeutics PLC HealthcareUnited States3.04
PTC Therapeutics Inc HealthcareUnited States2.97
Biogen Inc HealthcareUnited States2.95
GW Pharmaceuticals PLC ADR HealthcareUnited Kingdom2.92
Classification of Morningstar Category
Ranking1 Year2 Years3 Years5 Years
Top 25%
Category above the average
Category below the average
Bottom 25%
Morningstar Style Box
Equity Style
Large
Size
Mid
Small
Value
Blend
Growth
Style
$
43.72
Closing Price
All key information and documents must be reviewed before being able to Invest.